These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 15176704)

  • 1. [Pathophysiological significance and clinical utility of circulating osteoprotegerin].
    Dovio A; Data V; Angeli A
    Ann Ital Med Int; 2004; 19(1):8-19. PubMed ID: 15176704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?
    Dovio A; Data V; Angeli A
    J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
    Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
    Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report].
    Minenna G; D'Amore S; Maggiolini P; Scagliusi P; D'Amore M
    Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males.
    Oh KW; Rhee EJ; Lee WY; Kim SW; Baek KH; Kang MI; Yun EJ; Park CY; Ihm SH; Choi MG; Yoo HJ; Park SW
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):92-8. PubMed ID: 15638876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
    Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
    Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S; Kiyokawa A; Nagayama Y
    Clin Calcium; 2005 Jan; 15(1):35-42. PubMed ID: 15632471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
    Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.
    Rogers A; Eastell R
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6323-31. PubMed ID: 16105967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of RANK ligand involved in bone metabolism.
    Ito S; Hata T
    Vitam Horm; 2004; 67():19-33. PubMed ID: 15110169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
    Maïmoun L; Couret I; Mariano-Goulart D; Dupuy AM; Micallef JP; Peruchon E; Ohanna F; Cristol JP; Rossi M; Leroux JL
    Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
    Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
    Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
    Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
    J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.